Archive for month: August, 2019

Among 2 analysts covering ChemoCentryx (NASDAQ:CCXI), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. ChemoCentryx has $2400 highest and $22 lowest target. $23’s average target is 242.26% above currents $6.72 stock price. ChemoCentryx had 4 analyst reports since March 12, 2019 according to SRatingsIntel. The firm earned “Buy” rating on Tuesday, March 12 by H.C. Wainwright. The rating was upgraded by FBR Capital to “Buy” on Wednesday, March 27. See ChemoCentryx, Inc. (NASDAQ:CCXI) latest ratings:

06/06/2019 Broker: BidaskScore Rating: Buy Downgrade
06/06/2019 Broker: Inc. – Common Stock Rating: Raymond James New Target: $24.0000 17.0000
27/03/2019 Broker: FBR Capital Old Rating: Neutral New Rating: Buy Old Target: $12.5 New Target: $22 Upgrade
12/03/2019 Broker: H.C. Wainwright Rating: Buy New Target: $23 Maintain

Braun Stacey Associates Inc increased Target Corp (TGT) stake by 3.76% reported in 2019Q1 SEC filing. Braun Stacey Associates Inc acquired 5,207 shares as Target Corp (TGT)’s stock rose 14.18%. The Braun Stacey Associates Inc holds 143,648 shares with $11.53 million value, up from 138,441 last quarter. Target Corp now has $43.14B valuation. The stock increased 2.00% or $1.65 during the last trading session, reaching $84.21. About 4.71 million shares traded. Target Corporation (NYSE:TGT) has risen 6.39% since August 17, 2018 and is uptrending. It has outperformed by 6.39% the S&P500. Some Historical TGT News: 15/03/2018 – Cramer argues that the powers of Amazon, Walmart and Target coalesced to push Toys R Us into bankruptcy; 06/03/2018 – Target’s Same-Store Sales Surpass Expectations; 23/05/2018 – Target 1Q Comparable Average Transaction Amount Fell 0.6%; 03/05/2018 – SALLY BEAUTY HOLDINGS INC – AARON JOINS SALLY BEAUTY HOLDINGS FROM TARGET CORPORATION; 28/03/2018 – Companies interested in the locations include Target, Aldi, Big Lots and some real estate investment trusts; 23/05/2018 – Target 1Q Traffic Rose 3.7%; 23/03/2018 – Target And Kroger In Merger Talks: Report — MarketWatch; 05/04/2018 – Target settles claims it screened blacks, Hispanics out of jobs; 23/05/2018 – TARGET CORP – QTRLY COMPARABLE SALES GROWTH OF 3.0 PERCENT; 06/03/2018 – Target: January Comparable Sales Rose More Than 4%

ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, develops medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. The company has market cap of $391.44 million. The Company’s lead drug candidate is Avacopan , an orally-administered small molecule that is a selective inhibitor of the complement C5a receptor (C5Ar), which is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis (AAV). It currently has negative earnings. The firm also engages in developing CCX140, an inhibitor of the chemokine receptor known as CCR2 for patients with focal segmental glomerulosclerosis (FSGS), a debilitating kidney disease; Vercirnon for the treatment of patients with moderate-to-severe CrohnÂ’s diseases; CCX872, a selective inhibitor of the human CCR2 that has completed Phase I clinical trial for the treatment of pancreatic cancer; CCX507, which has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and Th17 cells for the treatment of psoriasis, rheumatoid arthritis, asthma, and multiple sclerosis.

Investors sentiment increased to 1.44 in Q1 2019. Its up 0.51, from 0.93 in 2018Q4. It is positive, as 12 investors sold ChemoCentryx, Inc. shares while 27 reduced holdings. 22 funds opened positions while 34 raised stakes. 33.34 million shares or 22.88% more from 27.13 million shares in 2018Q4 were reported. Dorsey Wright And holds 585 shares. Moreover, Point72 Asset Management L P has 0.03% invested in ChemoCentryx, Inc. (NASDAQ:CCXI). State Bank Of America Corporation De stated it has 92,817 shares. Sg Americas Secs Ltd Co has 20,240 shares for 0% of their portfolio. Renaissance Techs Lc owns 0.01% invested in ChemoCentryx, Inc. (NASDAQ:CCXI) for 1.13 million shares. Qs Ltd Liability Company owns 643 shares or 0% of their US portfolio. 9,979 were reported by One Trading Ltd Partnership. The New York-based Citigroup Inc has invested 0% in ChemoCentryx, Inc. (NASDAQ:CCXI). Strs Ohio reported 0% stake. Carmignac Gestion invested in 0.32% or 1.97M shares. Wells Fargo And Mn has 0% invested in ChemoCentryx, Inc. (NASDAQ:CCXI). Alliancebernstein L P stated it has 46,500 shares or 0% of all its holdings. Marshall Wace Llp holds 0.02% of its portfolio in ChemoCentryx, Inc. (NASDAQ:CCXI) for 132,410 shares. Moreover, Sectoral Asset has 0.03% invested in ChemoCentryx, Inc. (NASDAQ:CCXI). State Of Wisconsin Inv Board holds 30,100 shares or 0% of its portfolio.

More notable recent ChemoCentryx, Inc. (NASDAQ:CCXI) news were published by: Nasdaq.com which released: “ChemoCentryx (CCXI) Reports Q2 Loss, Lags Revenue Estimates – Nasdaq” on August 05, 2019, also Seekingalpha.com with their article: “ChemoCentryx down 16% after Q2 revenue miss – Seeking Alpha” published on August 06, 2019, Seekingalpha.com published: “ChemoCentryx, Inc. 2019 Q2 – Results – Earnings Call Slides – Seeking Alpha” on August 06, 2019. More interesting news about ChemoCentryx, Inc. (NASDAQ:CCXI) were released by: Seekingalpha.com and their article: “ChemoCentryx, Inc. (CCXI) CEO Thomas Schall on Q2 2019 Results – Earnings Call Transcript – Seeking Alpha” published on August 06, 2019 as well as Globenewswire.com‘s news article titled: “ChemoCentryx to Hold Second Quarter 2019 Financial Results Conference Call on Monday, August 5, 2019 – GlobeNewswire” with publication date: July 31, 2019.

The stock increased 3.86% or $0.25 during the last trading session, reaching $6.72. About 483,011 shares traded. ChemoCentryx, Inc. (NASDAQ:CCXI) has declined 28.17% since August 17, 2018 and is downtrending. It has underperformed by 28.17% the S&P500. Some Historical CCXI News: 09/03/2018 – CCXI PLANS TO START DEVT AVACOPAN IN HIDRADENITIS SUPPURATIVA; 09/05/2018 – ChemoCentryx 1Q Loss/Shr 19c; 09/03/2018 ChemoCentryx 4Q EPS 80c; 09/03/2018 – ChemoCentryx 4Q Rev $56.3M; 03/04/2018 – ChemoCentryx Presenting at Conference Apr 9; 23/05/2018 – ChemoCentryx Announces Two Upcoming Presentations at the 55th ERA-EDTA Congress; 09/03/2018 – ChemoCentryx 4Q Net $39.7M; 22/03/2018 – ChemoCentryx Publishes Novel Findings of Role of CCR2 in Kidney Glomerulus, Supporting Advancement of CCR2 Inhibitor CCX140 in; 22/03/2018 – ChemoCentryx Publishes Novel Findings of Role of CCR2 in Kidney Glomerulus, Supporting Advancement of CCR2 Inhibitor CCX140 in the Treatment of Focal Segmental Glomerulosclerosis (FSGS); 09/03/2018 – ChemoCentryx Intends to Initiate Clinical Development of Avacopan in Hidradenitis Suppurativa by Yr-En

Braun Stacey Associates Inc decreased Tabula Rasa Healthcare Inc Com stake by 7,678 shares to 235,470 valued at $13.29M in 2019Q1. It also reduced Nucor Corp (NYSE:NUE) stake by 5,635 shares and now owns 29,248 shares. Eog Res Inc Com (NYSE:EOG) was reduced too.

Blue Bell Private Wealth Management Llc decreased its stake in Tri Continental Corp (TY) by 3.21% based on its latest 2019Q1 regulatory filing with the SEC. Blue Bell Private Wealth Management Llc sold 18,628 shares as the company’s stock 0.00% . The institutional investor held 561,309 shares of the company at the end of 2019Q1, valued at $14.76 million, down from 579,937 at the end of the previous reported quarter. Blue Bell Private Wealth Management Llc who had been investing in Tri Continental Corp for a number of months, seems to be less bullish one the $1.42B market cap company. The stock increased 0.92% or $0.24 during the last trading session, reaching $26.39. About 40,763 shares traded. Tri-Continental Corporation (NYSE:TY) has 0.00% since August 17, 2018 and is . It has by 0.00% the S&P500.

Bvf Inc decreased its stake in Chemocentryx Inc (CCXI) by 78.1% based on its latest 2019Q1 regulatory filing with the SEC. Bvf Inc sold 5.22 million shares as the company’s stock declined 38.33% . The hedge fund held 1.46 million shares of the health care company at the end of 2019Q1, valued at $20.34M, down from 6.69M at the end of the previous reported quarter. Bvf Inc who had been investing in Chemocentryx Inc for a number of months, seems to be less bullish one the $391.44 million market cap company. The stock increased 3.86% or $0.25 during the last trading session, reaching $6.72. About 441,537 shares traded. ChemoCentryx, Inc. (NASDAQ:CCXI) has declined 28.17% since August 17, 2018 and is downtrending. It has underperformed by 28.17% the S&P500. Some Historical CCXI News: 20/04/2018 – DJ Chemocentryx Inc, Inst Holders, 1Q 2018 (CCXI); 09/03/2018 – CCXI TO BEGIN AVACOPAN CLINICAL STUDIES IN HS BY ’18 END; 11/04/2018 – ChemoCentryx Announces Presentation During National Kidney Foundation 2018 Spring Clinical Meeting; 10/05/2018 – Invus Public Equities Advisors Exits Position in ChemoCentryx; 22/03/2018 – ChemoCentryx Publishes Novel Findings of Role of CCR2 in Kidney Glomerulus, Supporting Advancement of CCR2 Inhibitor CCX140 in the Treatment of Focal Segmental Glomerulosclerosis (FSGS); 09/03/2018 – ChemoCentryx Intends to Initiate Clinical Development of Avacopan in Hidradenitis Suppurativa by Yr-En; 03/04/2018 – ChemoCentryx Presenting at Conference Apr 9; 09/03/2018 – ChemoCentryx Expects to Utilize Between $65M-$75M Cash and Investments in FY18; 23/05/2018 – ChemoCentryx Announces Two Upcoming Presentations at the 55th ERA-EDTA Congress; 09/03/2018 – CCXI PLANS TO START DEVT AVACOPAN IN HIDRADENITIS SUPPURATIVA

Blue Bell Private Wealth Management Llc, which manages about $245.45 million and $214.03M US Long portfolio, upped its stake in Schwab U.S. Large (SCHX) by 4,586 shares to 277,478 shares, valued at $18.76M in 2019Q1, according to the filing.

Investors sentiment increased to 1.43 in Q1 2019. Its up 0.25, from 1.18 in 2018Q4. It improved, as 10 investors sold TY shares while 13 reduced holdings. 12 funds opened positions while 21 raised stakes. 3.95 million shares or 9.71% less from 4.38 million shares in 2018Q4 were reported. Northwestern Mutual Wealth Mngmt holds 0% or 2,031 shares in its portfolio. Royal Retail Bank Of Canada reported 0% stake. Moreover, Raymond James Financial Services Advsrs Inc has 0.04% invested in Tri-Continental Corporation (NYSE:TY) for 396,331 shares. Ancora Advsrs Ltd Liability Com holds 0.05% or 47,733 shares. Archford Cap Strategies Ltd Liability Corporation has invested 0.01% in Tri-Continental Corporation (NYSE:TY). Wesbanco Natl Bank holds 9,093 shares or 0.01% of its portfolio. Regions Fincl Corporation invested in 4,654 shares or 0% of the stock. Landscape Capital Mngmt Ltd Limited Liability Company reported 77,513 shares. First Republic Investment Incorporated reported 8,283 shares stake. Cwm Ltd Llc accumulated 0% or 935 shares. Moreover, First Advsrs Lp has 0% invested in Tri-Continental Corporation (NYSE:TY). Moreover, Wells Fargo & Mn has 0% invested in Tri-Continental Corporation (NYSE:TY). Advisory Net Lc holds 0% of its portfolio in Tri-Continental Corporation (NYSE:TY) for 328 shares. Hudock Cap Group Ltd Liability Company invested 0.01% of its portfolio in Tri-Continental Corporation (NYSE:TY). Cls Invs Ltd Liability Corporation holds 0% in Tri-Continental Corporation (NYSE:TY) or 78 shares.

More notable recent Tri-Continental Corporation (NYSE:TY) news were published by: Seekingalpha.com which released: “Tri-Continental declares $0.265 dividend – Seeking Alpha” on May 24, 2019, also Finance.Yahoo.com with their article: “Is The Liberty Braves Group (BATRA) A Good Stock To Buy? – Yahoo Finance” published on May 03, 2019, Seekingalpha.com published: “Global stocks downgraded by Morgan Stanley as growth slows – Seeking Alpha” on July 08, 2019. More interesting news about Tri-Continental Corporation (NYSE:TY) were released by: Seekingalpha.com and their article: “Tri-Continental declares $0.24 dividend – Seeking Alpha” published on March 08, 2019 as well as Businesswire.com‘s news article titled: “Tri-Continental Corporation Declares Fourth Quarter Distribution – Business Wire” with publication date: November 23, 2018.

Investors sentiment increased to 1.44 in Q1 2019. Its up 0.51, from 0.93 in 2018Q4. It increased, as 12 investors sold CCXI shares while 27 reduced holdings. 22 funds opened positions while 34 raised stakes. 33.34 million shares or 22.88% more from 27.13 million shares in 2018Q4 were reported. Hong Kong-based Fosun Intl has invested 0.08% in ChemoCentryx, Inc. (NASDAQ:CCXI). Ny State Common Retirement Fund reported 25,400 shares. Aqr Capital Mngmt Lc holds 22,364 shares or 0% of its portfolio. Prtn Ltd Liability holds 0.02% of its portfolio in ChemoCentryx, Inc. (NASDAQ:CCXI) for 19,820 shares. Sio Capital Management Limited Com stated it has 530,175 shares or 1.99% of all its holdings. Prudential Fincl reported 0% of its portfolio in ChemoCentryx, Inc. (NASDAQ:CCXI). Metropolitan Life Insur Com has invested 0.01% of its portfolio in ChemoCentryx, Inc. (NASDAQ:CCXI). Public Employees Retirement Of Ohio owns 99,284 shares for 0.01% of their portfolio. 81,534 were reported by Matarin Cap Mngmt Lc. Alliancebernstein Lp owns 0% invested in ChemoCentryx, Inc. (NASDAQ:CCXI) for 46,500 shares. Acadian Asset Mngmt Limited reported 0.05% stake. National Bank & Trust Of America De holds 92,817 shares or 0% of its portfolio. Proshare Advsr Ltd Limited Liability Company invested in 0% or 19,606 shares. 643 were accumulated by Qs Investors Limited Liability. D E Shaw stated it has 0% of its portfolio in ChemoCentryx, Inc. (NASDAQ:CCXI).

Bvf Inc, which manages about $999.89 million and $893.07 million US Long portfolio, upped its stake in Ac Immune Sa by 5.23M shares to 7.46M shares, valued at $37.65M in 2019Q1, according to the filing. It also increased its holding in Vical Inc by 993,211 shares in the quarter, for a total of 2.28M shares, and has risen its stake in Arcus Biosciences Inc.

More notable recent ChemoCentryx, Inc. (NASDAQ:CCXI) news were published by: Seekingalpha.com which released: “ChemoCentryx, Inc. (CCXI) CEO Thomas Schall on Q2 2019 Results – Earnings Call Transcript – Seeking Alpha” on August 06, 2019, also Nasdaq.com with their article: “ChemoCentryx (CCXI) Reports Q2 Loss, Lags Revenue Estimates – Nasdaq” published on August 05, 2019, Seekingalpha.com published: “ChemoCentryx down 16% after Q2 revenue miss – Seeking Alpha” on August 06, 2019. More interesting news about ChemoCentryx, Inc. (NASDAQ:CCXI) were released by: Globenewswire.com and their article: “ChemoCentryx to Hold Second Quarter 2019 Financial Results Conference Call on Monday, August 5, 2019 – GlobeNewswire” published on July 31, 2019 as well as Seekingalpha.com‘s news article titled: “InflaRx downdraft engulfs ChemoCentryx, down 28% premarket – Seeking Alpha” with publication date: June 05, 2019.

In this report, the Global Hidradenitis Suppurativa Treatment market is valued at USD XX million in 2017 and is expected to reach USD XX million by the end of 2025, growing at a CAGR of XX% between 2017 and 2025. Global Hidradenitis Suppurativa Treatment market has been broken down by major regions, with complete market estimates on the basis of products/applications on a regional basis.

Browse full research report at https://www.crystalmarketreport.com/global-hidradenitis-suppurativa-treatment-market-report-history-and-forecast-2014-2025-breakdown-data-by-companies-key-regions-types-and-application

Summary

Hidradenitis suppurativa is a rare, inflammatory skin condition that begins as small and painful pimples on the skin. This medical condition is most common between the ages of 20-40 years. Prevalence of hidradenitis suppurativa is three times more common in females than in males.

Considering the global scenario of the market, North America holds the largest market share due to various factors such as increasing cases of skin diseases and related medical complications.

In 2018, the global Hidradenitis Suppurativa Treatment market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% between 2019 and 2025.

This report studies the Hidradenitis Suppurativa Treatment market size by players, regions, product types and end industries, history data 2014-2018 and forecast data 2019-2025; This report also studies the global market competition landscape, market drivers and trends, opportunities and challenges, risks and entry barriers, sales channels, distributors and Porter’s Five Forces Analysis.

This report focuses on the global top players, covered

GlaxoSmithKline

Johnson & Johnson

Merck

Pfizer

AbbVie

Allergan

AstraZeneca

…

Market segment by Regions/Countries, this report covers

North America

Europe

China

Rest of Asia Pacific

Central & South America

Middle East & Africa

Market segment by Type, the product can be split into

Medications

Surgery

Others

Market segment by Application, the market can be split into

Hospitals

Clinics

Others

The study objectives of this report are:

To study and forecast the market size of Hidradenitis Suppurativa Treatment in global market.

To analyze the global key players, SWOT analysis, value and global market share for top players.

To define, describe and forecast the market by type, end use and region.

To analyze and compare the market status and forecast among global major regions.

To analyze the global key regions market potential and advantage, opportunity and challenge, restraints and risks.

To identify significant trends and factors driving or inhibiting the market growth.

To analyze the opportunities in the market for stakeholders by identifying the high growth segments.

To strategically analyze each submarket with respect to individual growth trend and their contribution to the market

To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

To strategically profile the key players and comprehensively analyze their growth strategies.

In this study, the years considered to estimate the market size of Hidradenitis Suppurativa Treatment are as follows:

History Year: 2014-2018

Base Year: 2018

Estimated Year: 2019

Forecast Year 2019 to 2025

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Key Stakeholders

Raw material suppliers

Distributors/traders/wholesalers/suppliers

Regulatory bodies, including government agencies and NGO

Commercial research & development (R&D) institutions

Importers and exporters

Government organizations, research organizations, and consulting firms

Trade associations and industry bodies

End-use industries

Available Customizations

With the given market data, QYResearch offers customizations according to the company’s specific needs. The following customization options are available for the report:

Further breakdown of Hidradenitis Suppurativa Treatment market on basis of the key contributing countries.

Detailed analysis and profiling of additional market players.

Browse full research report at https://www.crystalmarketreport.com/global-hidradenitis-suppurativa-treatment-market-report-history-and-forecast-2014-2025-breakdown-data-by-companies-key-regions-types-and-application

Reasons to Buy This Research Report

About Crystal Market Reports

Crystal Market Reports is a distributor of market research spanning 160 industries. Our extensive database consists of over 400,000 quality publications sourced from 400 plus publishers, this puts our research specialists in the unique position of been able to offer truly unbiased advice on what research provides the most valuable insights.

Contact Info.:-

Address: 90 State Street
Suite 700 Albany
New York 12207
Email: [email protected]
Web: https://www.crystalmarketreport.com

Post Views:
9

Even in the midst of drug pricing wars in the United States, prescription drug sales continue to rise thanks to an increase in novel medicines being developed for niche therapeutic areas.

Case in point, according to a research report from Evaluate Pharma, prescription drug sales are projected to top a staggering US$1.18 trillion by 2024, fueled by technologies such as cell and gene therapy.

Despite that astronomically high figure, a number of patents are set to expire between now and then, which could potentially damp sales.

That being said, Evaluate Pharma states that the most profitable drug sales are ones that have been on the market for years and will continue to rake in the cash between now and 2024.

Here’s a breakdown of what those drugs are, which companies are developing them and what the sales for each are projected to reach during the forecast period.

1. Humira

Projected 2019 to 2024 sales: US$103.95 billion

Humira, which is developed by Big Pharma behemoth AbbVie (NYSE:ABBV), entered the market in 2003 and treats a wide range of conditions, including: Crohn’s disease, rheumatoid arthritis, psoriatic arthritis, juvenile idiopathic arthritis, ulcerative colitis and ankylosing spondylitis.

Since its launch, the drug has been additionally approved in the US and the European Union (EU) for hidradenitis suppurativa as well as uveitis in the US, EU and Japan.

According to Evaluate Pharma, Humira raked in sales of US$136.55 billion in sales from the time of its launch to 2018. Total sales are estimated to reach US$240.5 billion by 2024, which is a far cry from its runner up in terms of drug sales.

Evaluate Pharma claims Humira will become the most successful drug in the industry by 2020.

2. Lipitor

Projected 2019 to 2024 sales: US$15.76 billion

Lipitor came onto the scene in 1997 and was developed by former pharmaceutical company Warner-Lambert, which was acquired by Pfizer (NYSE:PFE) in 2000.

Lipitor is a statin cholesterol medication to treat cardiovascular disease and dyslipidemia.

Between its approval and 2018, sales of Lipitor totaled US$164.43 billion according to Evaluate Pharma data, although its sales declined after it lost patent protection in 2011. While its sales are nowhere near what they used to be, it has been, until now, the best-selling drug of all time. By 2024, total sales of Lipitor are projected to reach US180.19 billion.

3. Enbrel

Projected 2019 to 2024 sales: US$31.66 billion

Enbrel falls under Amgen’s (NASDAQ:AMGN) umbrella and was approved by the US Food and Drug Administration (FDA) in 1998 to treat rheumatoid arthritis. It was originally developed by Immunex, which Amgen acquired in 2002.

Since the first approval, Enbrel has been indicated for polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, plaque psoriasis and pediatric plaque psoriasis.

In mid-August, Amgen secured its patent win for Enbrel against Sandoz, a division of Novartis (NYSE:NVS); the decision prohibits Novartis from launching a biosimilar to Enbrel.

Between 1998 and 2018, Enbrel sales reached US108.17 billion, with total sales estimated to be US$139.83 billion by 2024.

4. Rituxan

Projected 2019 to 2024 sales: US$24.57 billion

Rituxan was officially approved by the FDA back in 1997 by Genentech, a company that was acquired by Roche (OTCQX:RHHBY) in 2009 in a massive US$46.8 billion deal.

The drug has been approved by the regulatory agency to treat non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, microscopic polyangiitis, granulomatosis with polyangiitis and pemphigus vulgaris.

Over the course of its first 19 years on the market, sales of Rituxan generated US$111.5 billion, with total sales estimated to hit US$136.07 billion by 2024.

5. Revlimid

Projected 2019 to 2024 sales: US$69.95 billion

Revlimid is the newest drug on this list, with Celgene (NASDAQ:CELG) having received approval for the drug by the FDA in 2008.

The drug was initially indicated for multiple myeloma and has since been expanded to treat myelodysplastic syndromes and mantle cell lymphoma.

From approval to 2018, sales of Revlimid totalled US$53.69 billion. It is projected to be a bestseller in the industry between now and 2024 and is projected to reach total sales of US$123.64 billion by then. That being said, Evaluate Pharma indicates that its sales between now and 2024 will depend on the arrival of generic competition before Revlimid’s patent expires in 2022.

6. Remicade

Projected 2019 to 2024 sales: US$19.2 billion

Remicade was approved in 1998 with the FDA giving the nod to Janssen Biotech, a division of Johnson & Johnson (NYSE:JNJ).

The drug was first approved for Crohn’s disease and, since then, has been approved for a wide range of indications including rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, ulcerative colitis, pediatric Crohn’s disease, plaque psoriasis and pediatric ulcerative colitis.

From its approval to 2018, sales of Remicade totalled US$98 billion. The drug is expected to reach US$117.2 billion in total sales by 2024.

7. Epogen

Projected 2019 to 2024 sales: US$7.97 billion

Amgen received approval by the FDA for Epogen in 1989 to treat anemia in connection with chronic renal failure in patients on dialysis or not on dialysis. Since that first approval, Epogen has also been indicated for certain types of cancer, such as breast, non-small cell lung, head and neck, lymphoid and cervical.

During the first few decades of approval, Epogen sales totaled US$107.9 billion with sales by 2024 projected to hit a total of US$115.87 billion.

8. Herceptin

Projected 2019 to 2024 sales: US$26.92 billion

Herceptin is another drug developed by Roche’s Genentech, and it received FDA approval in 1998. Herceptin’s first approval was to treat overexpressing breast cancer. It later received approval for HER2-positive metastatic stomach cancer.

From its launch date until 2018, sales of Herceptin touched US$87.97 billion and are projected to reach a total of US$114.89 billion by 2024.

9. Avastin

Projected 2019 to 2024 sales: US$27.14 billion

Avastin is the result of a joint development between Genentech and Roche. It received FDA approval in 2004 to treat metastatic colorectal cancer, but it has since received approval for other cancers, such as breast, lung, glioblastoma multiforme, renal cell carcinoma, cervical, ovarian, fallopian tube and peritoneal.

Sales of Avastin generated US$87.13 billion between 2004 and 2018 and are projected to hit a total of US$114.27 billion by 2024.

10. Advair

Projected 2019 to 2024 sales: US$9.41 billion

Advair is a product developed by GlaxoSmithKline (NYSE:GSK) and received approval from the FDA in 1998. The drug’s intended treatment is for asthma and chronic bronchitis.

Between 1998 and 2018, sales of Advair were US$104.2 billion, and that total number is projected to hit US$113.61 billion by 2024.

Don’t forget to follow us @INN_LifeScience for real-time news updates

Securities Disclosure: I, Jocelyn Aspa, hold no direct investment interest in any company mentioned in this article.

Wasatch Advisors Inc increased Chemocentryx Inc (CCXI) stake by 6.08% reported in 2019Q1 SEC filing. Wasatch Advisors Inc acquired 141,341 shares as Chemocentryx Inc (CCXI)’s stock declined 38.33%. The Wasatch Advisors Inc holds 2.46 million shares with $34.23M value, up from 2.32M last quarter. Chemocentryx Inc now has $382.70 million valuation. The stock decreased 3.52% or $0.24 during the last trading session, reaching $6.57. About 453,549 shares traded. ChemoCentryx, Inc. (NASDAQ:CCXI) has declined 28.17% since August 15, 2018 and is downtrending. It has underperformed by 28.17% the S&P500. Some Historical CCXI News: 10/05/2018 – Invus Public Equities Advisors Exits Position in ChemoCentryx; 09/03/2018 – ChemoCentryx Expects to Utilize Between $65M-$75M Cash and Investments in FY18; 09/03/2018 – CHEMOCENTRYX INC QUARTERLY SHR $0.80; 13/03/2018 – CHEMOCENTRYX INC CCXI.O : JP MORGAN RAISES TARGET PRICE TO $16 FROM $13; 09/05/2018 – CHEMOCENTRYX INC – QTRLY DILUTED NET LOSS PER COMMON SHARE $0.19; 09/03/2018 – ChemoCentryx 4Q Rev $56.3M; 09/03/2018 – CCXI PLANS TO START DEVT AVACOPAN IN HIDRADENITIS SUPPURATIVA; 09/03/2018 ChemoCentryx 4Q EPS 80c; 09/03/2018 – CCXI TO BEGIN AVACOPAN CLINICAL STUDIES IN HS BY ’18 END; 09/03/2018 – ChemoCentryx 4Q Net $39.7M

Hsbc Holdings Plc decreased Advanced Micro Devices Inc (AMD) stake by 48.85% reported in 2019Q1 SEC filing. Hsbc Holdings Plc sold 534,249 shares as Advanced Micro Devices Inc (AMD)’s stock rose 13.58%. The Hsbc Holdings Plc holds 559,360 shares with $14.28 million value, down from 1.09 million last quarter. Advanced Micro Devices Inc now has $32.57B valuation. The stock decreased 0.78% or $0.24 during the last trading session, reaching $30. About 32.52M shares traded. Advanced Micro Devices, Inc. (NASDAQ:AMD) has risen 56.80% since August 15, 2018 and is uptrending. It has outperformed by 56.80% the S&P500. Some Historical AMD News: 27/04/2018 – BIOPHYTIS SA ALBPS.PA – MACUNEOS IS THE ONLY DRUG CANDIDATE IN CLINICAL DEVELOPMENT TO TREAT DRY AMD; 05/03/2018 – AUTOMODULAR – AMD CURRENTLY BELIEVES SETTLEMENT PROCEEDS IN RESPECT OF GM CLAIM MAY NOT BE RECEIVED FROM GENERAL MOTORS ON OR BEFORE MARCH 7, 2018; 26/04/2018 – Cramer says Advanced Micro Devices is a buy, but Whirlpool is a sell; 21/04/2018 – DJ Advanced Micro Devices Inc, Inst Holders, 1Q 2018 (AMD); 20/03/2018 – ADVANCED MICRO DEVICES – SECURITY ISSUES IDENTIFIED BY THIRD-PARTY RESEARCHERS ARE NOT RELATED TO AMD “ZEN” CPU ARCHITECTURE; 26/04/2018 – Dow rises about 200 points, Facebook and AMD jump after crushing earnings; 29/03/2018 – Fudzilla: AMD’s open-source Radeon Rays integrated into Unity engine; 25/04/2018 – AMD: Cryptocurrency-related Revenue Rose In First Quarter, But Headed For Decline — MarketWatch; 15/03/2018 – AMD Propels Tear-Free Gameplay Beyond the PC with Support for Radeon FreeSync™ Technology in Select Xbox One Consoles; 13/03/2018 – ADVANCED MICRO DEVICES – INVESTIGATING CTS LABS REPORT, WHICH CO GOT, TO UNDERSTAND METHODOLOGY & MERIT OF FINDINGS

Investors sentiment increased to 1.52 in 2019 Q1. Its up 0.21, from 1.31 in 2018Q4. It is positive, as 43 investors sold AMD shares while 129 reduced holdings. 102 funds opened positions while 159 raised stakes. 634.98 million shares or 5.37% more from 602.61 million shares in 2018Q4 were reported. Cornerstone Advisors invested 0% of its portfolio in Advanced Micro Devices, Inc. (NASDAQ:AMD). M&R has 480 shares. State Of New Jersey Common Pension Fund D holds 600,000 shares or 0.06% of its portfolio. Citigroup holds 0.01% or 284,368 shares. Stifel Corporation owns 243,987 shares or 0.02% of their US portfolio. Jaffetilchin Lc accumulated 11,433 shares. Jennison Ltd Limited Liability Company, New York-based fund reported 786,485 shares. Trust Of Vermont reported 78 shares stake. Wetherby Asset invested 0.05% in Advanced Micro Devices, Inc. (NASDAQ:AMD). Fred Alger Mgmt Inc holds 0.04% or 351,372 shares in its portfolio. Bb&T Ltd Liability Corporation holds 44,710 shares or 0.01% of its portfolio. Tci Wealth Advsr holds 0.03% of its portfolio in Advanced Micro Devices, Inc. (NASDAQ:AMD) for 2,348 shares. Commerce Bank reported 0.01% stake. Envestnet Asset Mngmt Inc has 18,771 shares. Baystate Wealth Mgmt Limited Liability Company holds 0% of its portfolio in Advanced Micro Devices, Inc. (NASDAQ:AMD) for 45 shares.

Hsbc Holdings Plc increased Abbott Labs (Put) (NYSE:ABT) stake by 173,600 shares to 297,100 valued at $23.75 million in 2019Q1. It also upped Ecolab Inc (Put) (NYSE:ECL) stake by 9,700 shares and now owns 14,700 shares. 3M Co (Call) (NYSE:MMM) was raised too.

Among 8 analysts covering Advanced Micro Devices (NASDAQ:AMD), 6 have Buy rating, 0 Sell and 2 Hold. Therefore 75% are positive. Advanced Micro Devices has $42 highest and $1700 lowest target. $33.22’s average target is 10.73% above currents $30 stock price. Advanced Micro Devices had 22 analyst reports since March 13, 2019 according to SRatingsIntel. The stock of Advanced Micro Devices, Inc. (NASDAQ:AMD) earned “Buy” rating by RBC Capital Markets on Wednesday, March 13. The firm has “Sell” rating by Morgan Stanley given on Monday, March 25. The stock of Advanced Micro Devices, Inc. (NASDAQ:AMD) has “Buy” rating given on Monday, April 8 by Bank of America. The stock of Advanced Micro Devices, Inc. (NASDAQ:AMD) has “Sell” rating given on Tuesday, March 19 by Morgan Stanley. Jefferies maintained the shares of AMD in report on Wednesday, March 20 with “Buy” rating. The firm has “Buy” rating given on Friday, June 21 by Wells Fargo. The firm has “Equal-Weight” rating by Morgan Stanley given on Wednesday, July 31. The company was maintained on Wednesday, March 20 by Rosenblatt.

More notable recent Advanced Micro Devices, Inc. (NASDAQ:AMD) news were published by: Seekingalpha.com which released: “AMD: High Ground Vs. Low Ground – Seeking Alpha” on August 15, 2019, also Nasdaq.com with their article: “Why Advanced Micro Devices Stock Rocketed Higher Today – Nasdaq” published on August 08, 2019, Seekingalpha.com published: “AMD target boosted for product execution – Seeking Alpha” on August 12, 2019. More interesting news about Advanced Micro Devices, Inc. (NASDAQ:AMD) were released by: Nasdaq.com and their article: “Advanced Micro Devices (AMD) 2nd Quarter Earnings: What to Expect – Nasdaq” published on July 30, 2019 as well as Benzinga.com‘s news article titled: “Crazy Action In AMD Options As Traders Take Sides In Volatile Market – Benzinga” with publication date: August 14, 2019.

Wasatch Advisors Inc decreased Zagg Inc (NASDAQ:ZAGG) stake by 208,853 shares to 1.27M valued at $11.56 million in 2019Q1. It also reduced Euronet Worldwide Inc (NASDAQ:EEFT) stake by 218,656 shares and now owns 2.39M shares. Aaon Inc (NASDAQ:AAON) was reduced too.

Investors sentiment increased to 1.44 in Q1 2019. Its up 0.51, from 0.93 in 2018Q4. It is positive, as 12 investors sold CCXI shares while 27 reduced holdings. 22 funds opened positions while 34 raised stakes. 33.34 million shares or 22.88% more from 27.13 million shares in 2018Q4 were reported. Northern Tru Corporation has 310,007 shares for 0% of their portfolio. Wasatch owns 0.37% invested in ChemoCentryx, Inc. (NASDAQ:CCXI) for 2.46 million shares. Zebra Cap Ltd Company invested in 12,853 shares. National Bank Of New York Mellon has 133,619 shares for 0% of their portfolio. Clarivest Asset Management Limited Co invested in 0.01% or 51,400 shares. Citigroup reported 6,829 shares stake. 132,410 are owned by Marshall Wace Llp. Sio Capital Management Limited owns 530,175 shares. Baker Bros Advsr Limited Partnership reported 207,029 shares stake. Ameriprise Financial holds 0% of its portfolio in ChemoCentryx, Inc. (NASDAQ:CCXI) for 261,396 shares. Invesco Limited, a Georgia-based fund reported 148,988 shares. Dorsey Wright Assocs holds 0% in ChemoCentryx, Inc. (NASDAQ:CCXI) or 585 shares. 55,800 were reported by Strs Ohio. Jacobs Levy Equity Mgmt Inc stated it has 51,190 shares. Employees Retirement Systems Of Ohio holds 99,284 shares or 0.01% of its portfolio.

Among 2 analysts covering ChemoCentryx (NASDAQ:CCXI), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. ChemoCentryx has $2400 highest and $22 lowest target. $23’s average target is 250.08% above currents $6.57 stock price. ChemoCentryx had 4 analyst reports since March 12, 2019 according to SRatingsIntel. The stock of ChemoCentryx, Inc. (NASDAQ:CCXI) earned “Buy” rating by FBR Capital on Wednesday, March 27. The company was maintained on Tuesday, March 12 by H.C. Wainwright.

More notable recent ChemoCentryx, Inc. (NASDAQ:CCXI) news were published by: Nasdaq.com which released: “ChemoCentryx (CCXI) Reports Q2 Loss, Lags Revenue Estimates – Nasdaq” on August 05, 2019, also Seekingalpha.com with their article: “ChemoCentryx down 16% after Q2 revenue miss – Seeking Alpha” published on August 06, 2019, Finance.Yahoo.com published: “ChemoCentryx Inc (CCXI) Q2 2019 Earnings Call Transcript – Yahoo Finance” on August 08, 2019. More interesting news about ChemoCentryx, Inc. (NASDAQ:CCXI) were released by: Nasdaq.com and their article: “ChemoCentryx to Hold Second Quarter 2019 Financial Results Conference Call on Monday, August 5, 2019 – Nasdaq” published on July 31, 2019 as well as Seekingalpha.com‘s news article titled: “ChemoCentryx, Inc. 2019 Q2 – Results – Earnings Call Slides – Seeking Alpha” with publication date: August 06, 2019.